The director of Iran’s Pasteur Institute, Alireza Biglarí, reiterated this Saturday that the Cuban Soberana 02 vaccine candidate, in which Iran has cooperated in the clinical trials, is 100% effective in preventing the worst consequences of COVID -19.
“The efficacy of 2 doses of the Soberana 02 vaccine and the booster dose, Soberana Plus, in the third phase of the Cuban clinical trial was 91.2%, with 100% effectiveness in serious cases and deaths,” said Biglari. according to the official Iranian news agency IRNA.
Análisis interino de eficacia clínica del esquema heterólogo de dosis de SOBERANA02 y una dosis de refuerzo de SOBERANA-Plus. Resultados finales de la eficacia clínica del esquema de dos dosis de SOBERANA02. https://t.co/9aVJuY7TFt
— Yury Valdés Balbín (@BalbinYury) July 9, 2021
Iranian Minister of Health Saíd Namakí reported on June 29 that his country had issued the permit for the emergency use of the Soberana 02 vaccine from the Finlay Vaccine Institute (IFV), in which Iran has cooperated in the clinical trials and which is produced locally by the Pasteur Institute.
The vaccination campaign in Iran is too slow due to the shortage of doses received from abroad, mainly of the Russian Sputnik V, the Chinese Sinopharm and the British-Swedish AstraZeneca.
Iran’s Technical and Customs Assistant, Mehrdad Yamali Orunaqi, reported this Saturday that “in the last six months eight million doses of coronavirus vaccines have been imported into the country.”
More than 6.7 million people, out of a population of over 80 million, have received at least one dose of a COVID-19 vaccine in Iran, most of them healthcare personnel and people over 70 years of age.
According to data given today by the Ministry of Health, a total of 3,355,786 people have been infected with the virus since the beginning of the pandemic, although more than 3 million have already overcome the disease, and 85,694 have died.
On July 8, the general director of the Finlay Vaccine Institute (IFV), Vicente Vérez, announced that Soberana 02, in its three-dose scheme with the Soberana Plus booster, had reached an efficacy of 91.2% against the symptomatic disease.
In an update released by the Institute, it was added that the efficacy for the prevention of death and severe systemic disease had been significantly higher; achieving 100% prevention.